Testing a new drug combo for untreated high-risk MDS
Treatments studied
Part of Cancer clinical trials.
This trial tests whether adding an experimental drug called bexmarilimab to standard azacitidine can help people newly diagnosed with high-risk MDS. Doctors want to see if the combination works better than azacitidine alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be newly diagnosed with higher-risk myelodysplastic syndromes (MDS) and not yet treated.
- Your bone marrow blasts (immature cells) should be less than 20%.
- You must be able to start azacitidine chemotherapy and be age 18 or older.
- Your kidney and liver function must be good enough, with a clear creatinine clearance of at least 30 mL/min.
- You must not have had any prior cancer treatment for MDS, except supportive care like blood transfusions.
- You cannot be a candidate for immediate stem cell transplant at the start of the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, AK117, combined with azacitidine for people newly diagnosed with high-risk myelodysplastic syndromes (MDS), a blood disorder. The goal is to see if the combination can help improve outcomes.
This trial tests a new drug (ICP-248) combined with standard treatment azacitidine for people with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). It aims to find out if the combo is safe and effective for those who haven't been helped by other treatments or cannot have strong chemotherapy.
This trial tests whether combining azacitidine with enasidenib helps people with myelodysplastic syndrome (MDS) that has an IDH2 mutation. It’s designed for people who are either new to “hypomethylating” treatment or whose MDS returned/worsened after it.
This trial tests a combination treatment (chemo drugs plus a growth-factor medicine) for people newly diagnosed with acute myeloid leukemia (AML) or certain high-risk myelodysplastic syndromes (MDS). It may help by targeting cancer cells in the blood and bone marrow and improving remission chances.
This trial tests a new oral medication (iadademstat) combined with a standard therapy called a hypomethylating agent for people with higher-risk myelodysplastic syndromes (MDS) or related blood cancers. The goal is to see if the combination is safe and effective.
This trial compares two MDS treatments: a combination of two medicines (azacitidine plus luspatercept) versus azacitidine alone. It is for people with high-risk MDS who have not been treated yet.
Hear when a new Higher-risk Myelodysplastic Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.